Compare TotalEnergies SE (TTE) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs 10X Genomics Inc — how do they compare? TotalEnergies SE trades at $86.59 (market cap $187.35B), while 10X Genomics Inc trades at $79.5 (market cap $9.92B). The key difference: TotalEnergies SE is far larger — about 18.9× 10X Genomics Inc's market cap, and TotalEnergies SE pays a 5.03% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TotalEnergies SE for 90 Days and 10X Genomics Inc for 92 Days on average.
| TTE | TXG | |
|---|---|---|
Market Cap | $187.35B | $9.92B |
Volume | 1,924,317 | 9,372,166 |
Sector | Energy | Health |
52-Week High | $93.60 | $97.74 |
52-Week Low | $57.39 | $11.48 |
Typical Hold Time | 90 Days | 92 Days |
Enterprise Value | $218.34B | $9.44B |
Dividend Yield | 5.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $86.02, up 2.43% with strong earnings beats in Q1 and Q2 2026. The stock shows attractive valuation metrics with P/E of 10.54 and P/S of 0.94, while maintaining solid profitability with 9.08% net margin. Recent news highlights $10 billion Argentina investment and strategic growth plans through 2030, though technical indicators signal bearish momentum with key support at $83-84 levels.
TTE presents value opportunity with discounted valuation and dividend growth strategy, but faces headwinds from declining revenue trends and bearish technical setup. The 17% upside to consensus price target of $95.33 and 55.88% analyst buy rating support bullish case, though investors should monitor oil price volatility and execution of new investments.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
